Orion Animal Health’s Bonqat® (pregabalin) announced that it has received positive CVMP opinion. The Committee for Medical Products for Veterinary Use (CVMP) of the European Medicines Agency (EMA) has recommended Bonqat® (pregabalin) for marketing authorisation in the European Union. The compound is recommended for alleviation of acute anxiety and fear associated with transportation and veterinary visits in cats. The final decision of the European Commission on the marketing authorisation is expected in the coming months. Pregabalin is a new active substance for veterinary use and it acts in the central nervous system by reducing the release of various neurotransmitters (glutamate and monoaminergic neurotransmitters), resulting in an anxiolytic effect. Orion has also submitted a new animal drug application for pregabalin to the U.S. Food and Drug Administration (FDA).